Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris.
Aim of the study was to evaluate anti-ischemic, hemodynamic and neurohumoral effects of bimakalim, a novel selective K(+)-channel opener, in patients with stable angina pectoris and reproducible ST-segment depression. 86 patients with angiographic signs of CAD were involved in two randomised, placebo-controlled, double-blind trials with single high (0.1, 0.3 or 0.6 mg) and low (0.025 or 0.05 mg) doses of oral bimakalim. The anti-anginal efficacy was evaluated by analysis of ST-segment depression within exercise or RV pacing. A parallel assessment of hemodynamic parameters was done by means of right-heart catheterization. Given in high doses, bimakalim acted as a potent vasodilator and decreased SBP by 15 mm Hg. This was associated with a reflex activation of sympathetic nervous system resulting in an increase in heart rate by 25 /min, a 14% rise of myocardial oxygen consumption and a 63% elevation of noradrenaline plasma level. Low doses of bimakalim had no significant effect on hemodynamics and oxygen consumption. In exercise-induced angina pectoris, administration of bimakalim was neither associated with attenuation of ST-segment depression nor resulted in prolongation of time to 0.1 mV ST-segment depression. The results of the present study suggest that bimakalim has a dose-dependent vasodilatatory activity but exerts no anti-ischemic benefits in patients with exercise-induced angina pectoris due to coronary artery disease.